In psoriasis clinical trials, T-cell or NK-cell counts remained stable with deucravacitinib treatment (56), which is in agreement with a lack of effect on this pathway. Conversely, JAK1,2,3 inhibitor trials showed short-term fluctuations, followed by fast declines in NK and slower declines in CD4, and CD8 cells (74, 75). This evidence concerns the gene JAK1 and psoriasis.